

## Index

### a

- acellular scaffolds 303
- active targeting 277–278
- adenovirus (ADV), detected by MRSW biosensors 29–30
- agglomeration-based sensing 6–7
- alloy-based nanoparticles, early transition metal 500–502
  - MRI contrast agents 125–126
  - spherical and anisotropic 489–502
  - synthesis 490–500
- alternating magnetic field (AMF), in hyperthermia 237–240
- aminosilane (AS)-coated nanoparticles 237–239
  - passive targeting 275–276
- analyte detection
  - chemical separation
  - electrochemical detection
  - high magnetic field gradient separation
  - nonelectrochemical methods
- anisometric metal oxide magnetic nanomaterials 431–479
  - core–shell nanoparticles 463–467
  - correlations between synthesis and magnetic behavior 457–478
  - ferrofluids 449–454
  - iron oxide nanowires and nanotubes 474–478
  - maghemite and magnetite nanotubes 455–456
  - magnetism in 433–441
  - nanocomposites 468–473
  - spherical and anisometric iron oxide particles 457–462
  - spherical and anisometric nanoparticles 443–449
  - synthesis methods 442–456
- anisotropic iron oxide nanomaterials, biofunctionalization 507
- anisotropic magnetic alloy nanomaterials 489–502
  - early transition metals 500–501
  - future perspectives 502
  - noble metals 490–500
- anisotropy energy, magnetic 435–436
- anisotropy energy barriers 440
- anisotropy enhancement, cobalt nanoparticles 619–620
- annexin 5-directed MNPs 230
- antibodies
  - active targeting 277
  - aptamers as alternative 203–204
  - phospholipid coating 379–380
- antibody-directed MNPs 225–226
- antibody fragment-directed MNPs 226–228
- antibody immunoassays, magnetosomes 420
- antibody-modified MMPNs (HER-MMPNs) 234–235
- aprotic condensation reactions, sol-gel 446
- aptamers, as alternative to antibodies 203–204
- aquohydroxo complexes 444
- Arg-Gly-Asp (RGD), in MRI 215–217
- arginine peptide, coating 379
- array methods, multiplexed detection 58–62
- arsenic trioxide (ATO) MNPs 231–232
- AS *see* aminosilane
- assay systems
  - magnetophoretic 93–97
  - *see also* immunoassays
- atherosclerosis imaging 152
- ATO *see* arsenic trioxide
- atomic moments, enhancement 618–619

- Au *see* gold
- Auger electron spectroscopy, cobalt nanomaterials 596
- autocombustion
  - cobalt ferrite–silica nanocomposites 468–472
  - metal salts precipitation 448
- average blocking temperature 438
- b**
- background variations, control of 40
- bacteria, characterization 409–412
- bacterial biosynthesis 399–422
- bacterial magnetosomes (BMs) 230, 407–419
  - biomedical 422–424
  - *see also* magnetosomes
- bio-barcode assays, based on magnetic microspheres 66
- bioavailability, surface coating for 191–193
- biocompatibility, surface coating for 191–193
- biodetection reaction 336
- biofunctionalization 345–628
  - cobalt nanomaterials 587–628
  - magnetic core–polymer shell nanoparticles 347–389
  - magnetosomes 399–422
  - polymer shell nanoparticles 522–530
  - spherical and anisometric metal oxide magnetic nanomaterials 431–479
  - spherical and anisotropic magnetic alloy nanomaterials 489–502
  - spherical and anisotropic iron oxide nanomaterials 507–532
- biogenic inorganic materials 405–407
- biological applications 211–214
- biomedical applications 399–422
  - biomineralization 405–406
  - future for biomedical magnetosomes 422–424
  - general synthetic methods 403–405
  - magnetic core–polymer shell nanoparticles 347–348
  - magnetosomes *see also* bacterial magnetosomes 407–418
  - novel biomedical magnetosome materials 419–422
  - requirements and specifications 401–403
  - safety aspects 401
- biomineralization
  - fundamentals 405–406
  - magnetosomes *see also* bacterial magnetosomes, 407–418
- biomolecule immobilization, surface adsorption 510
- biosensing
  - and diagnosis 1–164
  - magnetophoretic *see* magnetophoretic biosensing
- biosensors *see* magnetic relaxation switch biosensors
- biosynthesis, bacterial 399–422
- blood cells, in magnetic field 83
- blood pool imaging 151–152
- blood vessels, MNP applications 299–300
- BMPA *see* 2-bromo-2-methylpropionic acid
- BMs *see* bacterial magnetosomes
- bone, tissue engineering 297–298
- bone marrow imaging 148–149
- borosilicate (BS) particles, detected by IMP 108–109
- brain imaging 149–151
- brain tumor therapy 232–234
- breast cancer therapy 234–236
- 2-bromo-2-methylpropionic acid (BMPA)-stabilized Fe<sub>3</sub>O<sub>4</sub> nanoparticles 268–269
- Brownian relaxation frequency measurements, DNA sequence detection 201–202
- BS *see* borosilicate
- BSA surface-imprinting 380
- c**
- cancer diagnosis
  - agents 214–232
  - MNPs used in (table) 243
- cancer diagnostics
  - aptamers 203–204
  - circulating tumor cells 202–203
  - *in vivo* and *in vitro* 189–205
  - MRI 194–197
  - surface coating of MNPs 191–193
- cancer imaging
  - agents 214–232
  - annexin 5-directed MNPs 230
  - ligand-directed MNPs 225–228
  - MNPs used in MR imaging 214–219
  - MNPs used in optical imaging 219–224
  - radioimmunonanoparticles 228–229
  - synthesis and surface modifications of MNPs 211–212
- cancer therapy 230–242
  - brain tumor 232–233
  - breast cancer 234–236

- chemotherapeutic drugs 230–231
  - hyperthermia and thermal ablation 237–239
  - lymph node-targeting MNPs 231
  - MNPs-directed toxicity 240–242
  - novel MNPs 231–232
  - targeted 232–242
  - cantilever detection, non-optical methods 578–579
  - CAP system (commercial diagnostic kit) 94
  - carbon shells
    - encapsulation 530
    - inorganic stabilization 319–324
  - cardiac structure, MNP applications 299–300
  - Carr-Purcell-Meiboom-Gill *see* CPMG
  - cartilage, MNP applications 297–298
  - CCD *see* charge-coupled device
  - cefradine loaded chitosan 382
  - cell-based SELEX (systematic evolution of ligands by exponential enrichment) 203
  - cell seeding, scaffolds and 3-d structures 296–297
  - cell separation
    - and analysis 102–104
    - direct 78
    - indirect 78
  - cells
    - detected by MRSW biosensors 34–36
    - tissue engineering with MNPs 291–303
  - cellular labeling and tracking 152–154
  - charge-coupled device (CCD)-mounted microscopic system 85, 87–88
  - chemical mechanical polishing (CMP) process 84–86
  - chemical separations, with functionalized MNPs 324–327
  - chemical vapor deposition (CVD), cobalt nanoparticles 602–603
  - chemiluminescence antibody immunoassays, magnetosomes 420
  - chemotherapeutic drugs, loaded with MNPs 230–231
  - chitosan 382
  - chlorotoxin (CTX)
    - in MRI 216–219
    - tumor targeting 196
  - circulating tumor cells (CTCs), detection of 202–203
  - cisplatin 382–384
  - clinical applications 123
    - MRI contrast agents 145–163
  - CLIO *see* crosslinked iron oxide
  - CMP *see* chemical mechanical polishing
  - CNT probes, magnetic force microscopy 565
  - coating 191–193, 402–403
    - and surface functionalization 129–138
  - arginine peptide 379
  - core-shell magnetic nanomaterials 264–266
  - herceptin 377–379
  - iodinated polymer 374–375
  - lipid micelles 373–374
  - MNP synthesis 350–357
  - phospholipid 379–380
  - PLGA and PLLA 372–373
  - poly(MMA-co-EGDMA) 380
  - poly(styrene-co-acrylic acid) 375
  - polypyrrole 376–377
- cobalt-based nanoparticles *see* cobalt nanoparticles
  - cobalt ferrite-silica nanocomposites, magnetic properties 468–472
  - cobalt nanomaterials
    - analysis 596
    - characterization 587–621
    - chemical analysis 596
    - electron microscopy 588–593
    - FTIR spectroscopy 597–598
    - hydrothermal synthesis 608
    - infrared spectroscopy 597–598
    - magnetic properties 593–594
    - morphology 594–596
    - nonhydrolytic organometallic thermolysis 609
    - photoelectron spectroscopy 596
    - polymer-assisted approach 605
    - shape 588–593
    - size 588
    - structure analysis 598
    - synthesis and characterization 587–621
    - TEM 588–590
    - XPS 596
    - XRD 598
  - cobalt nanoparticles 598
    - anisotropy enhancement 619–620
    - core, exchange bias 620
    - crystal phases 599
    - crystalline structure 613–614
    - CVD 602–603
    - exchange bias in 620
    - finite size effects 613
    - liquid-phase chemical precipitation 603–612
    - magnetic properties 612

- oxidized surface 620
  - physical synthesis methods 601
  - reversal 614–615
  - size-dependent magnetic domain structure 614–615
  - stabilization 599–601
  - structure 613–614
  - superparamagnetism 616–618
  - surface effects 618–621
  - synthesis 601–612
  - coercivity, thermal-activation effect 615–616
  - colloidal stability, MNPs 358
  - condensed matter, magnetism 433–435
  - contamination detection 312
  - contrast agents
    - improved 161–163
    - *see also* MRI contrast agents
  - convection-enhanced delivery (CED) 197
  - cooled magnetization 438–439
  - cooperative magnetism 433–434
  - coprecipitation
    - dextran-coated MNPs 350–352
    - metal oxide nanoparticles 314–315
    - PEG-coated MNPs 353–354
    - starch-coated MNPs 352–353
  - core fabrication 211
  - core–shell magnetic nanomaterials 451–455
    - active targeting 277–278
    - applied in drug delivery 279–281
    - applied in hyperthermia and thermal ablation 273–279
    - applied in MRI 270–273
    - coating with gold 264–266
    - coating with silica 266–268
    - coprecipitation from solution 260–261
    - double-coating with silica and gold 268–270
    - fluorescent magnetic iron oxide–silica 452–453
    - formation of core–shell structure 263–270
    - formation of magnetic core 260–263
    - in medical diagnosis and therapy 259–281
    - inorganic core with inorganic shell 264
    - inorganic core with organic shell 263
    - microemulsions 262
    - passive targeting 275–276
    - polymer 347–348
    - pyrolysis 262–263
    - size distribution 466–468
    - synthesis 260–270
    - thermal decomposition 261
  - CPMG sequences 13–14
  - CREKA (Cys-Arg-Glu-Lys-Ala) peptides 235
  - crosslinked dextran (Cy5.5-CLIO), in optical imaging 223–224
  - crosslinked iron oxide (CLIO) nanoparticles 5
    - fabrication of 212
  - crosslinked poly(maleic anhydride-alt-1-tetradecene) 373–374
  - crystalline structure
    - size-dependent 613–614
    - XRD 598
  - CTCs *see* circulating tumor cells
  - CTX *see* chlorotoxin
  - CVD *see* chemical vapor deposition
  - Cy5.5-CLIO *see* crosslinked dextran
- d**
- decomposition *see* high-temperature decomposition; thermal decomposition
  - dehydration, surfactant-assisted 450–451
  - dendrimer-mediated gene delivery 389
  - dendrimers
    - ligand exchange 532
    - nanoparticle functionalization 530–533
  - Desulfovibrio magneticus* 409
  - detection
    - analyte 324–336
    - cantilever 578–579
    - electrochemical 330–334
    - environmental 311–313
  - dextran-coated MNPs 350–352
    - passive targeting 275
  - dextran polymers 351
  - diagnosis 187–281
    - agents 214–232
    - and biosensing 1–164
    - cancer *see* cancer diagnosis
    - *in vivo* and *in vitro* 189–204
    - lateral flow devices 64–66
    - using magnetophoretic assay systems 93–97
    - *see also* magnetic resonance imaging
  - dispersions (ferrofluids), nanoparticle 459–461
  - DLVO theory 600
  - DNA, detected by MRSW biosensors 21–23
  - DNA sequence detection, by Brownian relaxation frequency measurements 201–202
  - domain structure, size-dependent 614–615

dopamine, PEG coating 361  
doxorubicin (DOX) 386–388  
– loaded BMs 230  
drinking water, pollution 311  
drug carriers, magnetic-targeted 230  
drug delivery, with core–shell magnetic  
nanomaterials 279–281  
drug/gene delivery system,  
nanospheres 380–389  
Dy oxide nanocrystals, MRI contrast  
agents 125

## e

early transition metal alloy  
nanoparticles 500–502  
electrochemical detection 330–334  
electrochemical immunoassays,  
improvements by MNPs 198  
electrohydrodynamic (EHD) encapsulation,  
of MNPs 193  
electron microscopy, cobalt  
nanomaterials 588–593  
elemental analysis, cobalt  
nanomaterials 596  
encapsulation 371–389  
– carbon shells 530  
– electrohydrodynamic 193  
– metallic and semiconductor  
shells 519–522  
– nanoparticle functionalization 516–530  
– polymeric 371–389, 522–530  
– silica 517–518  
engineered iron oxide nanoparticles  
(MEIO) 226–228  
environmental applications 309–336  
– future perspective 336  
– role of nanomaterials 311–312  
– separation and detection  
of analytes 324–336  
– synthesis and functionalization of  
MNPs 313–324  
enzymes, detected by MRSW  
biosensors 25–29  
exchange bias 620  
eye, tissue engineering 301–302

## f

F3-targeted polymeric MNPs 233–234  
FA *see* folic acid  
 $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>, tube-in-tube nanostructures  
477  
 $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>/silica core, coated with gold  
nanoshell 464–466

Fe<sub>3</sub>O<sub>4</sub>  
– nanowires 475  
– tube-in-tube nanostructures 477  
Fe<sub>3</sub>O<sub>4</sub>/polymethylmethacrylate 473–474  
Ferristene® (Abdoscan®), clinical  
applications 123  
ferrofluids 449–451, 459–461  
ferromagnetic materials  
– magnetic force microscopy 570–571  
– properties 80  
Ferucarbotran (SHU-555A, Resovis®),  
clinical applications 123  
Feruglose (NC100150, Clariscan®), clinical  
applications 123  
Ferumoxide (AMA-25; Feridex® or  
Endorem®), MRI contrast agent 272  
Ferumoxides (AMI-2, Endorem®/Feridex®),  
clinical applications 123  
Ferumoxsil (AMI-121, Lumirem®/  
GastroMARK®), clinical applications 123  
Ferumoxtran (Sinerem®, Combidex®), MRI  
contrast agent 272  
Ferumoxtran-10 (AMI-227, BMS-180549,  
Sinerem®/Combidex®), clinical  
applications 123  
Ferumoxytol (Code 7228), clinical  
applications 123  
FIB *see* focused ion beam  
fibroblasts  
– bone tissue engineering 296  
– dermal 300–301  
– repair of blood vessel damages 299  
field-cooled magnetization 438–439  
finite size effects, cobalt nanoparticles 613  
first-generation MRI contrast  
agents 271–273  
fluorescein isothiocyanate (FITC)  
– in optical imaging 220–221, 223  
fluorescence resonance energy transfer  
(FRET), in enzyme detection 27  
fluorescent magnetic composite  
nanoparticles (FMCNP) 453  
fluorescent magnetic iron oxide–silica  
particles 452–453  
fluorescent microbeads 92  
5-fluorouracil (5-FU)-linked MNPs 231,  
384–386  
FMCNP *see* fluorescent magnetic  
composite nanoparticles  
focused ion beam (FIB) probes,  
MFM 564–565  
folic acid (FA)  
– active targeting 277

- detected by MRSW biosensors 31–32
- functionalization 386–388
- polypyrrole coating 376–377
- force gradient detection 560
- force microscopy
  - magnetic *see* magnetic force microscopy
  - magnetic resonance 555
- fourier transform infrared (FTIR) spectroscopy, cobalt nanomaterials 597–598
- free radical copolymerization, PEG coating 363
- FRET *see* fluorescence resonance energy transfer
- FTIR *see* fourier transform infrared spectroscopy
- 5-FU *see* 5-fluorouracil
- functional MRI (f-MRI) 119–120
- functionalization 317–324
  - biological 507–533
  - chemical separations 324–327
  - encapsulation 516–530
  - inorganic stabilization 319
  - ligand exchange 511–512
  - lipids and dendrimers 530–533
  - monolayer reactions 515
  - organic ligand modification 318
  - other passivation methods 324
  - silanes and siloxanes 513–514
  - stabilization with polymers 319
  - surface adsorption 509–510
  - wet synthetic techniques 404
  - with FA 386–388
- g**
- gastrointestinal tract and bowel imaging 145–146
- Gd-DTPA chelates, MRI contrast agents 126–128
- Gd oxide nanocrystals, MRI contrast agents 125
- gemcitabine 382–384
- gene delivery 380–389
  - chitosan loaded with cefradine 382
  - dendrimer-mediated 389
  - PAMAM-dendrimer-mediated 389
  - PECA or PCL loaded with cisplatin or gemcitabine 382–383
  - PEI-mediated 388–389
  - PHDCA-PEI loaded with DOX 386
  - PLGA loaded with QDs and DOX 386–387
  - PLGA loaded with taxol 381
- PLLA and PCL loaded with tamoxifen 381
- poly(alkylcyanoacrylate) loaded with tegafur or 5-fluorouracil 384–385
- transferrin-mediated 388–389
- genetics, bacteria characterization 417–418
- glucose, detected by MRSW biosensors 31–32
- glycol-coated MNPs 355
- gold coating
  - core-shell magnetic nanomaterials 264–270
  - $\gamma$ -Fe<sub>2</sub>O<sub>3</sub>/silica core 464–466
- gradient separation 327–330
- grafting, polymer 359
- gram-negative bacteria 409
- green fluorescent protein (GFP), detected by MRSW biosensors 23–24
- h**
- HaCaT-ras-A-5RT3 tumors, MRI with RGD-USPIO particles 216–217
- heavy-metal contamination 312
- hemagglutinin (HA) peptide, detected by MRSW biosensors 31–32
- Herceptin (HER)
  - modified MMPNs 234–235
  - PPY coating 377–379
- herpes simplex virus (HSV-1), detected by MRSW biosensors 29–30
- HGMS *see* high-gradient magnetic separation
- high-boiling solvent, thermal decomposition 315
- high-gradient magnetic separation (HGMS) 79, 81–83, 327–330
  - and highly sensitive biosensors 92–93
- high-surface-area sorbent materials, pollution detection 329
- high-temperature decomposition 348
  - 4-methylcatechol-coated 355–357
  - MPEG-COOH-coated MNPs 354–355
  - triethylene glycol-coated MNPs 355
  - *see also* thermal decomposition
- highly sensitive biosensors, using HGMS 92–93
- horseradish peroxidase (HRP), detected by MRSW biosensors 28
- human chorionic gonadotropin (hCG), detected by MRSW biosensors 24–25
- human fibroblasts, MNPs 351
- hydrodynamic size, PCS 140
- hydrophobic-hydrophilic phase transfer 450–451

hydrothermal synthesis 317  
 – cobalt nanomaterials 608  
 hydrothermal treatment,  
 surfactant-assisted 448–449  
 hydroxylation reactions, sol-gel 446  
 hyperthermia  
 – MNPs as heating mediators 237–240  
 – passive targeting 275–276  
 – survival rates 239  
 – with core–shell magnetic  
 nanomaterials 273–279  
 hyperthermia/thermal ablation therapy,  
 laser-induced 278

## i

IEP *see* isoelectrophoresis  
 IgE *see* immunoglobulin E  
 IgG *see* immunoglobulin G  
 imaging 209–244  
 – atherosclerosis 152  
 – blood pool 151–152  
 – bone marrow 148–149  
 – bowel 145–146  
 – brain 149–151  
 – cancer *see* cancer imaging  
 – gastrointestinal tract 145–146  
 – invasive 553–554  
 – liver 146–147  
 – lymph node 147–148  
 – lymphotropic nanoparticle-enhanced  
 magnetic resonance 215  
 – magnetic force microscopy 553–554  
 – magnetic resonance *see* magnetic  
 resonance imaging  
 – molecular 154–159  
 – nanospheres 372–375  
 – noninvasive 554–555  
 – optical 219–224  
 – spleen 146–147  
 – targeted 137–138  
 imaging agents 214–232  
 imaging hardware, improved 161  
 imaging methods, improved 160  
 immunoassay improvements  
 – by MLNPs 199  
 – by MNPs 198–199  
 immunoassays  
 – magnetophoretic sandwich 89–92  
 – magnetosomes 420  
 – microfluidic *see* microfluidic  
 immunoassays  
 – multiplexed magnetophoretic  
 97–102  
 – *see also* assay systems

immunoglobulin E (IgE), detection  
 94–97  
 immunoglobulin G (IgG)  
 – detection 90–91, 98–102  
 IMP *see* isomagnetophoresis  
 imprintation, poly(MMA-*co*-EGDMA)  
 coating 380  
*in vitro* diagnostics 197–202  
 – Brownian relaxation frequency  
 measurements 201–202  
 – immunoassay improvements 198–199  
 – magnetic relaxation switch  
 biosensors 199–200  
*in vivo* diagnostics, MRI 194–196  
 infrared spectroscopy, cobalt  
 nanomaterials 597–598  
 inorganic coatings, surface  
 modification 133–136  
 inorganic cores  
 – with inorganic shell 264  
 – with organic shell 263  
 inorganic materials, biogenic 405–407  
 inorganic stabilization 319–324  
 invasive imaging, magnetic force  
 microscopy 553–554  
 iodinated polymer coating 374–375  
 ion channel activation 294  
 ions, detected by MRSW biosensors  
 32–34  
 iron oxide nanocapsules 453–455  
 iron oxide nanomaterials 442–457  
 – biofunctionalization 507  
 – ferrofluids 459–461  
 – magnetic behavior 457–479  
 – preparation 314  
 – spherical and anisometric 457–463  
 – synthesis and magnetic  
 behavior 457–479  
 iron oxide nanowires 474–475  
 iron oxide–silica particles,  
 fluorescent 452–453  
 isoelectrophoresis (IEP) 107  
 isomagnetophoresis (IMP) 107–111  
 IST direct investigation, cobalt  
 nanoparticles 616–618

## l

laser-induced hyperthermia/thermal ablation  
 therapy 278  
 laser pyrolysis, core–shell magnetic  
 nanomaterials 263  
 lateral flow diagnostic devices 64–66  
 lateral resolution, magnetic force  
 microscopy 568–569

- LHRH *see* luteinizing hormone-releasing hormone
- life sciences, application of MFM 576–578
- ligand-directed MNPs, for cancer imaging 225–228
- ligand exchange
- dendrimers 532
  - nanoparticle functionalization 511–513
- ligand modification, organic 318–319
- ligands
- systematic evolution of *see* SELEX
  - targeting 376–379
- lipid micelles coating 373–374, 379–380
- lipids, nanoparticle functionalization 530–533
- liposomes, magnetic cationic 276
- liquid-phase chemical precipitation 603–612
- liver, tissue engineering 302
- liver and spleen imaging 146–147
- LNMRI *see* lymphotropic nanoparticle-enhanced magnetic resonance imaging
- lung, tissue engineering 301
- luteinizing hormone-releasing hormone (LHRH) 236
- lymph node imaging 147–148
- lymph node-targeting MNPs 231
- lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) 215
- m**
- mAbs *see* monoclonal antibodies
- MACS *see* magnetic-activated cell sorting
- maghemite ( $\gamma\text{-Fe}_2\text{O}_3$ )
- anisometric particles 462–463
  - nanotubes 455
  - synthesis 260–270
  - *see also* core–shell magnetic nanomaterials
- magnetic-activated cell sorting (MACS) 78
- magnetic alloy nanomaterials
- characterization 489–502
  - spherical and anisotropic 489–502
  - synthesis 489–502
- magnetic anisotropy energy 435–436
- magnetic bacteria, biomineralization 407–419
- magnetic cationic liposomes, passive targeting 276
- magnetic composite nanoparticles, fluorescent 453
- magnetic core, formation of 260–263
- magnetic core–polymer shell nanoparticles 347–348
- magnetic domain structure, size-dependent 614–615
- magnetic early transition metal alloy nanoparticles 500–502
- magnetic energy sources, comparison of 84
- magnetic field gradient separation 327–330
- magnetic-fluid-aminosilane(MFL AS)-coated nanoparticles 237–239
- magnetic fluid-induced hyperthermia (MFH) 237–239
- magnetic force microscopy (MFM) 551–580
- calibration samples 567–568
  - cantilever oscillation 556–558
  - cantilevers and probes 562
  - characterization of MNPs 551–580
  - comparison to other techniques 553–555
  - development 551–553, 578–580
  - dynamic mode 556–559
  - external magnetic fields 579
  - FIB probes 564–565
  - forces 559–560
  - lateral resolution 568–569
  - life sciences 576–578
  - limitations 577–578
  - magnetic interaction 559–560
  - modes 555–559
  - noise 560–562
  - noninvasive imaging 554–555
  - physical principals 555–560
  - probe calibration 565–568
  - probes 562, 564–565
  - quantitative calibration 566–567
  - recent developments 578–580
  - resolution 568–569
  - Si probes 563–564
  - signals 561–562
  - static mode 555–556
  - technique developments 579–580
  - thermal noise 560–562
  - thin-film-coated Si probes 563–564
  - topographic signals 561–562
  - vertical resolution 569
  - wire probes 563
- magnetic ion channel activation (MICA) bioreactor 295
- bone tissue engineering 297–298
- magnetic iron oxide–silica particles, fluorescent 452–453



- magnetic luminescent nanoparticles (MLNPs), immunoassay improvements 199
- magnetic metal oxide nanoparticles, synthetic strategies 313–317
- magnetic metal oxides 440–442
- magnetic microspheres
  - bio-barcode assays 66
  - spectrally encoded suspension arrays 66–72
- magnetic nanomaterials
  - alloy *see* magnetic alloy nanomaterials
  - anisometric metal oxide *see* anisometric metal oxide magnetic nanomaterials
  - anisotropic *see* anisotropic magnetic alloy nanomaterials
  - cobalt *see* cobalt nanomaterials
  - core–shell *see* core–shell magnetic nanomaterials
  - ferromagnetic *see* ferromagnetic materials
  - oxide *see* oxide nanomaterials
  - spherical iron oxide *see* spherical iron oxide nanomaterials
- magnetic nanoparticle suspensions, properties and characterization 138–145
- magnetic nanoparticles (MNPs)
  - novel 231–232
  - physico-chemical characterization 212–214
  - physico-chemical properties 190–191
- magnetic particles, and magnetism 56–58
- magnetic relaxation switch ... *see also* MRSW ...
- magnetic relaxation switch biosensors
  - agglomeration-based sensing 6–7
  - characterization 36–38
  - demonstrations 20–36
  - detecting cells 34–36
  - detecting enzymes 25–29
  - detecting ions 32–34
  - detecting nucleic acids 21–23
  - detecting proteins 24–25
  - detecting small molecules 30–32
  - detecting viruses 29–30
  - for multi-sample analysis 199–200
  - $T_2$  sensitivity of MRSW particles 8–18
  - kinetics 18–20
  - measurement enhancement methods 38–42
  - methods development 36–42
  - micro-NMR 42–46
  - nanomaterials-based 3–46
  - preparation 36–38
  - reagent synthesis 36–38
  - sensitivity enhancement methods 38–42
  - superparamagnetic nanoparticles 4–6
- magnetic resonance force microscopy 555
- magnetic resonance imaging (MRI)
  - 145–159, 214–219
  - functional 119–120
  - *in vivo* diagnostics 194–196
  - lymphotropic nanoparticle-enhanced 215
  - MNPs 219–224
  - monitoring of treatment 196–197
  - principles 194
  - specific targeting of tumors 195–196
  - with core–shell magnetic nanomaterials 270–273
  - *see also* MRI
- magnetically encoded suspension arrays, of magnetic microspheres 70–72
- magnetism, and magnetic particles 56–58
- magnetite ( $\text{Fe}_3\text{O}_4$ )
  - nanotubes 455
  - PDMS nanoparticles 466–468
  - spherical 457–459
  - synthesis 260–270
  - *see also* core–shell magnetic nanomaterials
- magnetization
  - thermoremanent 439–440
  - zero field-cooled and field-cooled 438–439
- magneto-polymeric nanohybrids (MMPNs) 234–236
- Magnetobacterium bavaricum* 411
- magnetometric assays, use of MNPs 58
- magnetometry, magnetic properties of contrast agents 139
- magnetophoresis
  - design and microfabrication processes 83–85
  - experimental set-up 85–88
  - fundamentals 80–81
  - in microfluidic devices 83–88
  - measurement and analysis 88
- magnetophoretic assay systems, in disease diagnosis 93–97
- magnetophoretic biosensing 77–112
  - high-gradient magnetic separation 81–83
  - magnetic properties of materials 79–80
  - magnetophoresis 80–81
  - sandwich immunoassay 89–92
  - theory 79–83
- magnetophoretic immunoassay systems, comparison with a CAP system 96–97

- magnetophoretic sandwich
  - immunoassay 89–92
- magnetophoretic separation 102–111
  - cell separation and analysis 102–104
  - high-gradient magnetic separation 81–83
  - magnetic properties of materials 79–80
  - magnetophoresis 80–81
  - of nanomaterials 104–107
  - SWCNTs 104–106
  - theory 79–83
- magnetoresistive sensors 58–59
- magnetosomes 399–422
  - biomedical 422–424
  - characterization 412–415
  - formation 415
  - magnetic properties 402
  - progress and applications of novel materials 419–422
  - requirements for particles 400–405
  - *see also* bacterial magnetosomes
- Magnetospirillum magnetotacticum* 409
  - genetics 417
  - protein analyses 416
- Magnetospirillum vibros* 412
- maleic anhydride-alt-1-tetradecene, crosslinked 373–374
- MAP *see Mycobacterium avium paratuberculosis*
- MBE *see* molecular beam epitaxy
- mechanotransduction, tissue engineering 293–295
- medical applications *see* biomedical applications
- MEIO *see* engineered iron oxide nanoparticles
- mesenchymal stem cells (MSCs), labeling with SPIOs 300
- mesoporous  $\gamma\text{-Fe}_2\text{O}_3/\text{SiO}_2$  nanocomposites 472–473
- metal-based nanoparticles, MRI contrast agents 125–126
- metal oxide nanoparticles
  - magnetism in 433–442
  - synthesis and characterization 431–479
  - synthetic strategies 313–317
- metal salts precipitation, water 443–445
- methoxyPEG-Aspn coating 363
- 4-methylcatechol-coated MNPs 355–357
- MFH *see* magnetic fluid-induced hyperthermia
- MFL AS *see* magnetic-fluid-aminosilane
- MFM *see* magnetic force microscopy
- MICA *see* magnetic ion channel activation
- micelles coating 373–374
- micro-NMR, MRSW biosensors 42–46
- microbeads, fluorescent 92
- microemulsions 317
  - core-shell magnetic nanomaterials 262
  - metal salts precipitation 447–448
- microfluidic particle sorting, principles 103
- microfluidic immunoassays 89
  - detection of IgE 94–97
  - detection of IgG 90–91, 98–102
  - using SMNPs 89
- microfluidic magnetophoresis, experimental set-up 87
- microparticles (MP),  $T_2$  sensitivity enhancement 41–42
- microscopic system, CCD-mounted 85
- microscopy *see* different types
- MIONs *see* monocrystalline iron oxide nanoparticles
- MLNPs *see* magnetic luminescent nanoparticles
- MMPNs *see* magneto-polymeric nanohybrids
- MNP *see* magnetic nanoparticles
- MNP synthesis, coating 350–357
- MNPs-directed toxicity 240–242
- molecular beam epitaxy (MBE) 601
- molecular imaging 154–159
- monoclonal antibodies (mAbs), tumor targeting 196
- monocrystalline iron oxide nanoparticles (MIONs) 5
- monolayer reactions, nanoparticle functionalization 515–516
- monomeric stabilizers 129–130
- mononuclear phagocyte system (MPS), nanoparticle removal 350
- MP *see* microparticles
- MPEG-COOH-coated MNPs 354–355
- MPS *see* mononuclear phagocyte system
- MR angiography 151–152
- MR lymphangiography (MRL) 231
- MR pulse sequences 13–14
- MRI ... *see also* magnetic resonance imaging
- MRI contrast agents 119–163
  - application of magnetic nanomaterials 145–159
  - approved for clinical applications or clinically tested 123
  - atherosclerosis imaging 152
  - blood pool imaging and MR angiography 151–152
  - bone marrow imaging 148–149

- brain imaging 149–151
  - cellular labeling and tracking 152–154
  - classification 121–128
  - coating and surface functionalization 129–138
  - current clinical applications 145–152
  - different generations of 271–273
  - gastrointestinal tract and bowel imaging 145–146
  - improved 161–163
  - liver and spleen imaging 146–147
  - lymph node imaging 147–148
  - magnetic oxide-based nanoparticles 122–125
  - magnetometry 139
  - molecular imaging 154–159
  - NMR dispersion 141
  - photon correlation spectroscopy 140
  - potential clinical applications 152–159
  - properties and characterization 138–145
  - SPIOs 195
  - TEM 139
  - vectorization for targeted imaging 137–138
  - MRL *see* MR lymphangiography
  - mRNA, detected by MRSW biosensors 22
  - MRSW ... *see also* magnetic relaxation switch ...
  - MRSW multiplexing 45
  - MRSW particles,  $T_2$  sensitivity 8–18
  - MSCs *see* mesenchymal stem cells
  - multi-sample analysis, with magnetic relaxation switch biosensors 199–200
  - multiplexed detection 55–72
  - multiplexed magnetophoretic immunoassay 97–102
  - Mycobacterium avium paratuberculosis* (MAP), detected by MRSW biosensors 34–35
  - myeloperoxidase (MPO), detected by MRSW biosensors 28
- n**
- nanocapsules 453–455
  - nanocomposites
    - magnetic properties 468–472
    - ordered mesoporous  $\gamma\text{-Fe}_2\text{O}_3/\text{SiO}_2$  472–473
  - nanomagnet detection 552
  - nanomaterials
    - magnetic *see* magnetic nanomaterials
    - magnetic properties 79–80
    - role in environmental detection 311–313
  - nanoparticle–analyte aggregates 7
  - nanoparticle clusters, and SPM theory 143–144
  - nanoparticle dispersions (ferrofluids) 459–461
  - nanoparticle-polymer materials, comparison 523–525
  - nanoparticles (NP)
    - core–shell *see* core–shell nanoparticles
    - magnetic *see* magnetic nanoparticles
    - superparamagnetic 4–6, 571–576, 616–618
  - nanospheres 380–389
    - imaging 372–375
    - targeting and recognition capability 375–380
  - nanowires and nanotubes
    - $\text{Fe}_3\text{O}_4$  475–477
    - iron oxide 474
    - maghemite and magnetite 455
    - solid template 455–456
    - soluble template 456
  - nervous tissue, engineering 302–303
  - nickel electroplating, microfluidic magnetophoresis 86
  - NMR *see* nuclear magnetic resonance
  - NMRD *see* nuclear magnetic resonance dispersion
  - noble metal alloy nanoparticles 490–500
  - non-optical methods, cantilever detection 578–579
  - nonelectrochemical methods 334
  - nonhydrolytic organometallic thermolysis, cobalt nanomaterials 609
  - noninvasive imaging, magnetic force microscopy 554–555
  - NP *see* nanoparticles
  - NP-PEG-CTX, in MRI 218
  - NP-PEG-SIA, in MRI 218
  - nuclear magnetic resonance (NMR) detection
    - micro-NMR 42–46
    - principle 9
  - nuclear magnetic resonance dispersion (NMRD), measuring magnetic resonance properties 141
  - nucleic acids, detected by MRSW biosensors 21–23
- o**
- Oersted treatment level 241
  - opsonization 191
  - optical imaging, MNPs 219–224

- organometallic thermolysis, cobalt nanomaterials 609
  - oxide nanocapsules 453–455
  - oxide nanomaterials 122–125, 433–442
    - biofunctionalization 507
    - spherical and anisometric 457–463
    - synthesis and characterization 431–479
    - synthesis and magnetic behavior 457–479
  - oxidized surface, exchange bias in cobalt nanoparticles 620
- p**
- paramagnetic materials 571–576
    - properties 79
  - particle size
    - by TEM 139
    - effect of synthesis conditions 349
    - effect on magnetic properties 466–468
  - particle size and shape, requirements for biomedical applications 402
  - particle sorting, by microfluidic technology 103
  - particles *see* magnetic nanoparticles; nanoparticles
  - passivation, less common methods 324
  - passive targeting, core–shell magnetic nanomaterials 275–276
  - PCL *see* poly( $\epsilon$ -caprolactone)
  - PCS *see* photon correlation spectroscopy
  - PDMS *see* poly(dimethylsiloxane)
  - PECA *see* poly(ethyl-2-cyanoacrylate)
    - cisplatin loaded 382–384
  - PEG ... *see also* poly(ethylene glycol)
  - PEG coating
    - coprecipitation method 353–354
    - dopamine 361
    - free radical copolymerization 363
    - silane 360
  - PEG-PAsp coating 362
  - PEG-PEI, lipid micelles coating 373–374
  - PEGMA coating 368
  - PEI, gene delivery 388–389
  - peptides, active targeting 277
  - pharmacokinetic profile, of MNPs 212–214
  - phase transfer, hydrophobic–hydrophilic 450–451
  - PHDCA-PEI, doxorubicin loaded 386
  - D-phenylalanine (D-Phe), detected by MRSW biosensors 30–31
  - phospholipid coating 379–380
  - photoelectron spectroscopy, cobalt nanomaterials 596
  - photon correlation spectroscopy (PCS), measuring hydrodynamic size 140
  - plasma stability, of MNPs 212–214
  - PLGA
    - QD- and DOX-loaded 386–388
    - taxol loaded 381
  - PLGA coating 372–373, 379
  - PLLA, tamoxifen loaded 381–382
  - PLLA coating 372–373
  - PMMA *see* poly(methyl methacrylate)
  - pollution detection, high-surface-area sorbent materials 329
  - poly( $\epsilon$ -caprolactone) (PCL) nanoparticles 231, 382–384
    - tamoxifen loaded 381–382
  - poly(L-lysine) coating 364
  - poly(alkylcyanoacrylate) 384–386
  - poly(dimethylsiloxane) (PDMS)
    - effect of particle size and particle size distribution 466–468
    - micromolding 83–86
  - poly(ethyl-2-cyanoacrylate) (PECA) nanoparticles 230–231
  - poly(ethylene glycol) (PEG)
    - polymer coatings 192
    - *see also* PEG
  - poly(maleic anhydride-alt-1-tetradecene) 373–374
  - poly(methyl methacrylate) (PMMA) particles, detected by IMP 108–111
  - poly(MMA-co-EGDMA) coating 380
  - poly(styrene-co-acrylic acid) coating 375
  - polyamidoamine (PAMAM) 389
  - polymer adsorption, onto preformed MNPs 357–359
  - polymer-assisted approach, cobalt nanomaterials 605
  - polymer coating 191–193, 350–357
    - iodinated 374–375
  - polymer encasement 319
  - polymer grafting 359
  - polymer shell nanoparticles 350–371
    - biofunctionalization 522–530
  - polymeric matrix, encapsulation of MNPs 371–389
  - polymeric stabilizers 319
    - surface modification 130–133
  - polymethylmethacrylate 473–474
  - polypyrrole coating 376–377
  - polysaccharide dextran, polymer coatings 192
  - polysaccharide structures 526

- polystyrene (PS) particles, detected by  
   IMP 108–111  
 polyvinyl pyrrolidone (PVP), cobalt  
   nanomaterials 606  
 PPY coating, herceptin 377–379  
 precipitation 403–405  
   – metal salts 443–445  
 preconcentration 327–330  
   – enhanced electrochemical  
   detection 330–334  
 preformed MNPs  
   – grafting of polymer 359  
   – modification 357–371  
   – physical adsorption 357–359  
 probe calibration  
   – MFM 565–568  
   – quantitative 566–567  
 proteins, detected by MRSW  
   biosensors 24–25  
 proteomics, bacteria  
   characterization 416–417  
 PS *see* polystyrene
- q**
- quantum dots (QDs)  
   – in optical imaging 220  
   – PLGA loading 386–388
- r**
- radioimmunonanoparticles  
   (RINPs) 228–229  
 rare earth metal-loaded nanoparticles, MRI  
   contrast agents 126–128  
 rare earth oxide nanocrystals, MRI contrast  
   agents 125  
 RBCs *see* red blood cells  
 RCA *see* rolling circle amplification  
 recognition capability,  
   nanospheres 375–380  
 red blood cells (RBCs), in magnetic  
   field 83  
 relaxation  
   – Brownian 201–202  
   – in the presence of superparamagnetic  
   nanoparticles 141–143  
   – *see also* magnetic relaxation switch  
   biosensors;  $T_2$  relaxation  
 relaxation time measurements, general  
   application 144–145  
 relaxivity  
   – classification of MRI contrast  
   agents 121–122  
   – longitudinal and transverse 14–15  
   resolution (MFM)  
   – lateral 568–569  
   – vertical 569  
   reticuloendothelial system (RES) 191  
   – coating of MNPs 213  
   reversal, of Co nanoparticles 614–615  
   RGD *see* Arg-Gly-Asp  
   RGD-USPIO particles 215–217  
   RNA, short interfering 236  
   RNPs *see* radioimmunonanoparticles  
   rolling circle amplification (RCA), DNA  
   sequence detection 201  
   rotating discs 63
- s**
- safety aspects, and biomedical  
   applications 401–402  
 salts precipitation, water 443–445  
 sandwich immunoassay,  
   magnetophoretic 89–92  
 scaffolds  
   – tissue engineering 296–297, 303  
 scanning electron microscopy  
   (SEM) 590–593  
 SCLC *see* small cell lung cancer  
 second-generation MRI contrast  
   agents 271–273  
 selective capture, analyte 327  
 SELEX (systematic evolution of ligands by  
   exponential enrichment), cell-based 203  
 SEM *siehe* scanning electron microscopy  
 semiconductor shells,  
   encapsulation 519–522  
 sensors  
   – agglomeration-based 6–7  
   – magnetoresistive 58–59  
   – *see also* biosensors  
   separating and mixing, magnetic  
   particles 58  
   separation  
   – chemical 324–327  
   – magnetophoretic *see* magnetophoretic  
   separation  
   – MNPs 324–336  
   – of analytes 324–336  
   short interfering RNAs (siRNAs) 236  
   SHU-555C (Supravist®), clinical  
   applications 123  
   Si probes  
   – coated 563–564  
   – magnetic force microscopy 563–564  
   silane  
   – nanoparticle functionalization 513–515

- PEG coating 360
- silica (SiO<sub>2</sub>)
  - encapsulation 517–518
  - fluorescent 452–453
  - inorganic stabilization 319–324
  - nanoparticle functionalization 517–519
- silica coating 320
  - core–shell magnetic nanomaterials 266–270
- silica core, coated with gold nanoshell 464–466
- silica nanocomposites, magnetic properties 468–472
- siloxanes, nanoparticle functionalization 513–515
- single-walled carbon nanotubes (SWCNTs), separation 104–106
- siRNAs *see* short interfering RNAs
- size-dependent magnetic domain structure, cobalt nanoparticles 614–615
- skin, tissue engineering 300–301
- small cell lung cancer (SCLC) cells, aptamer application 204
- small molecules, detected by MRSW biosensors 30–32
- small particles, magnetism 436–440
- SMNPs *see* superparamagnetic nanoparticles
- sol–gel autocombustion technique, cobalt ferrite–silica nanocomposites 468–472
- sol–gel process, metal salts precipitation 445–447
- solid nanotube template 455–456
- soluble nanotube template 456
- solvothermal synthesis, cobalt nanomaterials 608
- spectrally encoded suspension arrays, of magnetic microspheres 66–72
- spherical and anisometric metal oxide magnetic nanomaterials, characterization 431–479
- spherical iron oxide nanomaterials
  - biofunctionalization 507
  - synthesis methods 442–457
- spherical iron oxide particles 457–463
- spherical magnetic alloy nanomaterials 489–502
- spherical magnetite (Fe<sub>3</sub>O<sub>4</sub>) nanoparticles 457–459
- spherical metal oxide magnetic nanomaterials, synthesis and characterization 431–479
- spherical nanoparticle dispersions (ferrofluids) 459–461
- spherical nanoparticles, synthesis 443–449
- spherical particles 451–455
- spin dephasing 9
- spin echo sequences 13–14
- spin valve sensors 59
- spinel structure, magnetic metal oxides 440
- SPIO *see* superparamagnetic iron oxide
- SPM theory, applied to suspensions of nanoparticle clusters 143–144
- spray pyrolysis, core–shell magnetic nanomaterials 262
- SQUID *see* superconducting quantum interference device
- stabilization
  - DLVO theory 600
  - of MNP surfaces 129–136
- stable iron oxide spherical nanoparticle dispersions (ferrofluids) 459–461
- starch-coated MNPs 352–353
- stem cells
  - mesenchymal 300
  - targeting 303
- super exchange, cooperative magnetism 434
- superconducting quantum interference device (SQUID) magnetometry 553
- superparamagnetic iron oxide nanoparticles (SPIONs) 4–5
  - as MRI contrast agents 195
  - inside a magnetic field 10
  - MRI applications 122–125
  - thermally crosslinked 221–222
- superparamagnetic nanoparticles (SMNPs) 4–6, 571–576
  - and NMR relaxation 141–143
  - Co 616–618
  - in immunoassays 89
- superparamagnetism, physics 437
- surface adsorption 509–511
- surface atoms, moment enhancement 618–619
- surface coating
  - and chemistry 211–212
  - for improved biocompatibility and bioavailability 191–193
- surface-imprinting 380
- surface-initiated polymerization 527
- surface modification 211–214
  - using inorganic coatings 133–136
  - using polymeric stabilizers 130–133

- with monomeric stabilizers 129–130
  - surface plasmon resonance, iron oxide nanoparticles 324
  - surface properties, effect of synthesis conditions 349
  - surfactant-assisted dehydration 450–451
  - surfactant-assisted hydrothermal treatment 448–449
  - surfactant-assisted ultrasound irradiation 449
  - surfactant effect, ferrofluids 461–462
  - survival rates, in hyperthermia 239
  - suspension arrays, spectrally encoded 66–72
  - SWCNTs *see* single-walled carbon nanotubes
  - synthesis
    - alloy-based nanoparticles 490–500
    - and functionalization 313–324
    - and surface modifications 211–214
    - anisometric metal oxide magnetic nanomaterials 442–456
    - bacterial 399–422
    - cancer imaging 211–212
    - cobalt-based nanoparticles 598–612
    - core–shell magnetic nanomaterials 260–270
    - correlations 457–479
    - effect on particle size and surface\_ properties 349
    - environmental applications 313–324
    - hydrothermal *see* hydrothermal synthesis
    - iron oxide nanomaterials 457–479
    - maghemite ( $\gamma\text{-Fe}_2\text{O}_3$ ) 260–270
    - magnetite ( $\text{Fe}_3\text{O}_4$ ) 260–270
    - metal oxide nanoparticles 431–479
    - oxide nanomaterials 431–479
    - physical methods 601–602
    - spherical and anisotropic\_iron oxide nanomaterials 508–533
    - spherical iron oxide nanomaterials 442–457
    - spherical metal oxide magnetic nanomaterials 431–479
    - spherical nanoparticles 443–449
    - transition metal alloy nanoparticles 500–502
  - synthesis methods
    - general 403
    - primary 348–350
  - synthesis/processing methods, classification of 211
  - synthesis strategies 313–317
- t**
- $T_2$  relaxation
    - and nanoparticle size (theoretical model) 14–18
    - detecting 11–14
    - fundamentals 8–11
    - $T_2$  sensitivity, of MRSW particles 8–18
  - tamoxifen 381–382
  - targeted cancer therapy 232–242
    - brain tumor therapy 232–234
    - breast cancer therapy 234–236
    - hyperthermia and thermal ablation 237–240
  - targeted imaging, vectorization of magnetic nanomaterials 137–138
  - targeting
    - nanospheres 375–380
    - novel MNPs 231–232
  - targeting ligands 379–380
    - arginine peptide 379
    - herceptin 377–379
    - polypyrrole coating 376–377
  - taxol, PLGA 381
  - TCL-SPIONs *see* thermally crosslinked SPIONs
  - tegafur 384–386
  - TEM *see* transmission electron microscopy
  - temperature decomposition *see* thermal decomposition
  - temperature-responsive polymers, coating 365
  - theranostic approach 240
  - therapy 187–281
    - brain tumor 232–234
    - breast cancer 234–236
    - cancer *see* cancer therapy
    - core–shell magnetic nanomaterials 259–281
    - hyperthermia/thermal ablation 278
    - thermo- 237–240
  - thermal ablation
    - MNPs as heating mediators 237–240
    - with core–shell magnetic nanomaterials 273–279
  - thermal activation effect, moment and coercivity 615–616
  - thermal decomposition 405
    - metal oxide nanoparticles 315–317
    - 4-methylcatechol-coated 355–357
    - MPEG-COOH-coated MNPs 354–355
    - triethylene glycol-coated mnps 355
    - *see* high-temperature decomposition

- thermally crosslinked SPIONs (TCL-SPIONs), in optical imaging 221–222
  - thermolysis, nonhydrolytic organometallic 609
  - thermoremanent magnetization (TRM) 439–440
  - thermotherapy 237–240
  - third-generation MRI contrast agents 271–273
  - tissue engineering 291–303
    - cell seeding 296–297
    - mechanotransduction 293–295
  - toxicity, MNPs-directed 240–242
  - transferrin-mediated gene delivery 388–389
  - transition metal alloy nanoparticles, synthesis 500–502
  - transmission electron microscopy (TEM)
    - cobalt nanomaterials 588–590
    - measuring nanoparticle size 139
  - treatment, surfactant-assisted 448–449
  - triethylene glycol-coated MNPs 355
    - decomposition 355
  - TRM *see* thermoremanent magnetization
  - tube-in-tube nanostructures 477
  - tumor targeting, for MRI 195–196
- u**
- ultrasmall paramagnetic iron oxide (USPIO) particles 209
    - MRI applications 122–124
    - RGD 215–217
  - ultrasmall SPIO (USSPIO) particles 5
  - ultrasound irradiation, surfactant-assisted 449
- v**
- vectorization, magnetic nanomaterials for targeted imaging 137–138
  - vertical resolution, MFM 569
  - viruses, detected by MRSW biosensors 29–30
  - VSOP-C184, clinical applications 123
- w**
- water, metal salts precipitation 443–445
  - wet synthetic techniques, biomedical functional MNPs 404
  - white blood cells (WBCs), in magnetic field 83
  - Wiedemann's additivity law 108
  - Wilcoxon rank sum comparisons 242
- x**
- X-ray diffraction (XRD), cobalt nanomaterials 598
  - X-ray photoelectron spectroscopy (XPS), cobalt nanomaterials 596
- z**
- zero field-cooled magnetization 438–439